Evidence map›Paper›PMID 38985127›Full record

ArticleAging2024

CALCR exacerbates renal cell carcinoma progression via stabilizing CD44.

Haiyang Yan, Zhaohui Xing, Shuai Liu, Peng Gao, Qingli Wang, Guiying Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haiyang YanDepartment of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Zhaohui XingDepartment of Urology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150036, China.
Shuai LiuDepartment of Urology, The Third Affiliated Hospital of Qiqihar Medical College, Qiqihaer, Heilongjiang 161099, China.
Peng GaoDepartment of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Qingli WangDepartment of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Guiying GuoDepartment of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calcitonin receptor (CALCR) is an essential protein for maintaining calcium homeostasis and has been reported to be upregulated in numerous cancers. However, the molecular role of CALCR in renal cell carcinoma (RCC) is not well understood. In this study, we identified the overexpression of CALCR in RCC using human tissue chip by immunohistochemical (IHC) staining, which was associated with a poor prognosis. Functionally, CALCR depletion inhibited RCC cell proliferation and migration, and induced cell apoptosis and cycle arrest. CALCR is also essential for

Indexed as

ApoptosisCarcinoma, Renal CellCell ProliferationDisease ProgressionHyaluronan ReceptorsKidney NeoplasmsAnimalsCalcitonin Receptor-Like ProteinCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMaleMiceReceptors, CalcitoninCalcitonin Receptor-Like ProteinCALCRL protein, humanCD44 protein, humanHyaluronan ReceptorsReceptors, CalcitoninCALCRCD44proliferationRCCubiquitination

Identifiers

PMID38985127
PMCPMC11272109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.